News from regado biosciences, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Apr 03, 2011, 14:15 ET

Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System

Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced...

Mar 30, 2011, 10:17 ET

Regado Biosciences to Present at the Needham & Company's 10th Annual Healthcare Conference in New York City

Regado Biosciences, a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced that David...

Mar 28, 2011, 12:09 ET
Feb 23, 2011, 10:17 ET

Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City

Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Ellen...

Nov 23, 2010, 10:17 ET

Regado Biosciences to Present at the 22nd Annual Piper Jaffray Health Care Conference in New York City and the Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference in San Francisco

Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J....

Nov 17, 2010, 10:30 ET

Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that...

Nov 16, 2010, 11:45 ET

Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that...

Nov 15, 2010, 12:00 ET
Nov 03, 2010, 10:32 ET

Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania

Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Ellen...

Nov 03, 2010, 10:17 ET

Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs

Regado Biosciences, Inc., a private biopharmaceutical company leading the development of antithrombotic aptamers with matched active control...

Nov 02, 2010, 19:30 ET

Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that...

Oct 26, 2010, 10:17 ET

Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City

Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J....

Sep 16, 2010, 10:17 ET

Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City

Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J....

Sep 09, 2010, 10:17 ET

Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts

Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J....

Jul 27, 2010, 10:17 ET

Regado Biosciences to Present at the 2010 Wedbush Securities Life Sciences Best Ideas MAC: Management Access Conference

Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J....

Jul 26, 2010, 16:05 ET

Regado Biosciences Announces Publication in the American Heart Association Journal Circulation of the Results of a Phase 2a Study for the REG1 Anticoagulant System in Elective Percutaneous Interventions

Regado Biosciences, Inc., a privately held biopharmaceutical company pioneering the development of a novel two-component antithrombotic drug...

Jun 17, 2010, 09:30 ET

Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts

Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J....

Jun 08, 2010, 09:30 ET

Regado Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference in New York City on June 11, 2010

Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J....

Jun 07, 2010, 09:30 ET

Regado Biosciences to Present at the 9th Annual Needham Healthcare Conference on June 10, 2010 in New York City

Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J....

May 25, 2010, 09:30 ET

Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, today announced...